50 results on '"Wojdyla, Daniel"'
Search Results
2. Abstract 14756: The Effect of Torsemide vs Furosemide Across the Renal Function Spectrum - Insights From the TRANSFORM-HF Trial
3. Abstract 14698: Effect of Torsemide vs. Furosemide Among Patients With New Onset and Worsening Heart Failure: The Transform-HF Randomized Trial
4. Graft Failure After Coronary Artery Bypass Grafting and Its Association With Patient Characteristics and Clinical Events: A Pooled Individual Patient Data Analysis of Clinical Trials With Imaging Follow-Up
5. Abstract 11994: Reduced versus Standard Dose Apixaban in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial
6. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM
7. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex
8. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients with Atrial Fibrillation After Acute Coronary Syndrome or PCI: Insights from The AUGUSTUS Trial
9. Apixaban versus Warfarin in Patients with Atrial Fibrillation and Advanced Chronic Kidney Disease
10. Abstract 15664: Prior Oral Anticoagulant Status and Outcomes in Patients With Atrial Fibrillation With an Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the Augustus Trial
11. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS
12. Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial
13. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial
14. Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial
15. Efficacy and Safety of Apixaban versus Warfarin in Patients with Atrial Fibrillation and Extremes in Body Weight: Insights from the ARISTOTLE Trial
16. Quantifying Importance of Major Risk Factors for Coronary Heart Disease
17. Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention: Report From the NCDR CathPCI Registry
18. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex
19. Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial
20. Predictive Utility of a Validated Polygenic Risk Score for Long-Term Risk of Coronary Heart Disease in Young and Middle-Aged Adults
21. Abstract 18003: Patients With Good Adherence to Study Medication Have Better Outcomes: Insights From the ARISTOTLE Trial
22. Abstract 16493: Variation in Patient Characteristics Does Not Explain Regional Differences in Outcomes: Findings From ARISTOTLE
23. Abstract 15115: Incidence, Timing, and Type of First and Recurrent Ischemic Events in Patients With and Without Peripheral Artery Disease After an Acute Coronary Syndrome
24. Abstract 14533: Association Between Operator PCI Volume and Long-term Outcomes in Older Adults: A Report From The NCDR CathPCI Registry
25. Abstract 13802: Appropriateness and Outcomes of Percutaneous Coronary Intervention at Top-Ranked and Non-Ranked Hospitals in the United States
26. Abstract 13760: Symptom Onset to Door Time and Door to Balloon Time: Can We Further Decrease Mortality Post STEMI?
27. Abstract 12512: Antithrombotic Strategies According to Age in Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the Augustus Trial
28. Abstract 10426: Worse Clinical Outcomes in Patients with Acute Coronary Syndrome and Prior or New Onset Heart Failure: Insights from 47,474 Patients in a Pooled Analysis of Randomized Clinical Trials
29. Abstract 9290: Relationship Between Body Weight and Pharmacokinetics of Apixaban in Patients With Atrial Fibrillation: Insights from the ARISTOTLE Trial
30. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention
31. Abstract P010: Do the Pooled Cohort Equations Accurately Predict Cardiovascular Disease Risk in Older Adults?
32. Response to Letters Regarding Article, 'Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Insights From PREVENT IV'
33. Response to Letters Regarding Article, “Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial”
34. Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes
35. Abstract 17277: Apixaban Use in Patients With Atrial Fibrillation With Bioprosthetic Valves: Insights From ARISTOTLE
36. Abstract 17236: Intracranial Hemorrhage in Patients With Atrial Fibrillation in the ARISTOTLE Trial: Clinical Characteristics and Associated Outcomes
37. Abstract 12873: Blood Transfusion and the Risk of Contrast-Induced Nephropathy Among Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
38. Abstract 17205: Polypharmacy and the Impact of Apixaban on Clinical Events in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial
39. Abstract 11084: Coronary Artery Bypass Graft Surgery in Elderly Patients With Multivessel Coronary Artery Disease is Associated with Better Outcomes
40. Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery
41. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
42. Response to Letter Regarding Article, “Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial”
43. Abstract 9790: Central Venous Pressure After Coronary Artery Bypass Surgery: Does it Predict Postoperative Mortality or Renal Failure?
44. Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes
45. Abstract 16903: Predictors of Major Bleeding Risk: Insights from the Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
46. Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial
47. Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function
48. Abstract 14836: Nsaid Use is Associated With Worse Outcomes but Similar Benefits of Apixaban Over Warfarin in Patients With Atrial Fibrillation: Results From the ARISTOTLE Trial.
49. Abstract 13187: Characteristics and Outcomes of Atrial Fibrillation in Patients With a Diagnosis of Thyroid Disease: An Analysis of the ARISTOTLE Trial.
50. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.